Trial Profile
Real Life Data for Otezla Evidence: Assessing Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms REALIZE
- Sponsors Amgen; Celgene Corporation
- 16 Nov 2021 Status changed from active, no longer recruiting to completed.
- 14 Dec 2020 Planned End Date changed from 24 Jun 2021 to 24 Oct 2021.
- 14 Dec 2020 Planned primary completion date changed from 24 Jun 2021 to 24 Oct 2021.